Navigation Links
Food and Drug Law Institute Sponsors Major Enforcement Conference
Date:12/20/2007

Top FDA and DOJ Officials, Legal Experts to Discuss Latest Criminal Cases, Decrees and How They Now Apply to Food and Dietary Supplement Industries

WASHINGTON, Dec. 20 /PRNewswire-USNewswire/ -- In the last year, mainstream drug and device companies have agreed to pay more than $1.9 billion in fines, civil settlements and penalties. Top drug company executives have paid multimillion dollar fines even though they did not participate in or know about the crimes.

With the Federal Government increasingly seeking legal action against pharmaceutical and device companies -- even those who didn't intend to do anything wrong -- there's a burgeoning need for food and drug industry stakeholder to stay current with federal enforcement developments.

To help meet those needs, the Food and Drug Law Institute is sponsoring its 6th Annual Conference on Enforcement & Litigation: Consent Decrees, Criminal Cases and Corporate Integrity Agreements, Feb. 19-20 at the L'Enfant Plaza Hotel in Washington, D.C.

At the conference, experts will discuss the latest enforcement actions and litigation and ways that voluntary implementation measures required by corporate integrity agreements and consent decrees can help food, drug and device firms stay clear of expensive and often demoralizing action.

Conferees will hear directly from Food and Drug Administration and Department of Justice officials, including luncheon speaker Gerald R. Masoudi, FDA's Chief Counsel and Eugene Thirolf, Director of DOJ's Office of Consumer Litigation. Other FDA officials include Deborah Autor, Director of Compliance, CDER; Joseph R. Baca, Director of Food Safety, CFSAN; Eric M. Blumberg, Deputy Chief Counsel for Litigation; Garry L. Coody, National Health Fraud Coordinator, Office of Enforcement, ORA; David K. Elder, Director, Office of Enforcement, Office of Regulatory Affairs; Annamarie Kempic, Associate Deputy for Litigation; Mary Anne Malarkey, Director, Office of Compliance & Biologics Quality, CBER; Vernessa T. Pollard, Associate Chief Counsel - Enforcement, OCC; Michael C. Rogers, Director, Office of Field Investigations, Office of Regulatory Affairs; Steven D. Silverman, Assistant Director, Officer of Compliance, CDER; Laura M. Tarentino, Office of Food Additive Safety, CFSAN; and Timothy A. Ulatowski, Director of Compliance, CDRH.

To register for the conference, visit http://www.fdli.org or call (800) 956-6923 or (202) 371-1420.

Founded in 1949, FDLI publishes the award-winning, peer-reviewed Food and Drug Law Journal; the bimonthly magazine Update; FDA Directory; and dozens of books and publications for attorneys, regulatory affairs practitioners, scientists, health care professionals, government employees and marketers in the food and drug field. For more information, visit http://www.fdli.org


'/>"/>
SOURCE Food and Drug Law Institute
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates
2. Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute
3. LifeNet Health Establishes The Skin & Wound Allograft Institute
4. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
5. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
6. Portico Systems to Share Provider Network Management Best Practices at Institute for International Research
7. The Integrated Benefits Institute Offers Largest Benchmarking Database in U.S. Spanning Disability and Workers Compensation Programs
8. The Cooper Institutes FITNESSGRAM Selected as Statewide Physical Fitness Assessment Tool
9. Bullying Prevention Institute Designed to Empower Change in Schools
10. Southern Research Institutes Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding
11. Corey McPherson Nash Develops Case Statement for Dana-Farber Cancer Institute Capital Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... As health professionals work to improve their approach to healthcare, there is ... than filling out a survey; in many cases health professionals and patients are working ... and research on the importance of active engagement with patients and members of the ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & Associates ... special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to date ... elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded by ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology: